Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Erlotinib Hydrochloride 19Bevacizumab 12Cisplatin 11Pemetrexed 6Carboplatin 6Gemcitabine 5onartuzumab 4Paclitaxel 4Docetaxel 3sintilimab 1parsatuzumab 1lifastuzumab vedotin 1imgatuzumab 1atezolizumab 1Vinorelbine 1Platinum Compounds 1Etoposide 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Non-Squamous Non-Small Cell Lung Cancer × imgatuzumab × Clear all
NCT01185847 2016-01-01

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Hoffmann-La Roche

Phase 2 Completed
90 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡